Education
About Us
Working with TipRanks
Follow Us
Bio-Rad Laboratories (BIO)
:BIO
BIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$244.00 - $387.99
Previous CloseN/A
Volume33.84K
Average Volume (3M)399.42K
Market Cap
$7.18B
Enterprise Value$9.12B
Total Cash (Recent Filing)$488.10M
Total Debt (Recent Filing)$1.20M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Apr 24, 2025EPS Estimate
1.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-65.04
Shares Outstanding22,940,805
10 Day Avg. Volume464,180
30 Day Avg. Volume399,424
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.80
Price to Cash Flow (P/CF)14.50
P/FCF Ratio13.20
Enterprise Value/Market Cap1.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.62
Enterprise Value/Ebitda-7.63
Forecast
1Y Price Target
$374.00Price Target Upside45.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Bio-Rad Laboratories News
PremiumCompany Announcements
Bio-Rad Laboratories Updates on Sartorius Investment
PremiumCompany Announcements
Bio-Rad’s Cautious Optimism Amid Earnings Challenges
PremiumCompany Announcements
Bio-Rad Laboratories Reports 2024 Earnings and Strategic Plans
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe CFO is focused on doubling free cash flow by improving inventory management and supplier terms.
Investment OpportunitiesMonetizing the Sartorius stake could add significant firepower for BIO to accelerate share buybacks, potentially reducing existing float by ~30%.
Management StrategiesNew management is executing strategies to improve margins and free cash flow.
Bears Say
Acquisition AspirationsHistoric aspirations for BIO to acquire all of Sartorius are now financially impossible due to massive dilution concerns.
Inventory ManagementInventory turns are significantly down compared to pre-COVID levels.
Working Capital ManagementThe company has more cash tied up in working capital than its peers, indicating inefficiencies.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BIO FAQ
What was Bio-Rad Laboratories’s price range in the past 12 months?
Bio-Rad Laboratories lowest stock price was $244.00 and its highest was $387.99 in the past 12 months.
What is Bio-Rad Laboratories’s market cap?
Bio-Rad Laboratories’s market cap is $7.18B.
When is Bio-Rad Laboratories’s upcoming earnings report date?
Bio-Rad Laboratories’s upcoming earnings report date is Apr 24, 2025 which is in 29 days.
How were Bio-Rad Laboratories’s earnings last quarter?
Bio-Rad Laboratories released its earnings results on Feb 13, 2025. The company reported $2.9 earnings per share for the quarter, beating the consensus estimate of $2.868 by $0.032.
Is Bio-Rad Laboratories overvalued?
According to Wall Street analysts Bio-Rad Laboratories’s price is currently Undervalued.
Does Bio-Rad Laboratories pay dividends?
Bio-Rad Laboratories does not currently pay dividends.
What is Bio-Rad Laboratories’s EPS estimate?
Bio-Rad Laboratories’s EPS estimate is 1.83.
How many shares outstanding does Bio-Rad Laboratories have?
Bio-Rad Laboratories has 22,940,805 shares outstanding.
What happened to Bio-Rad Laboratories’s price movement after its last earnings report?
Bio-Rad Laboratories reported an EPS of $2.9 in its last earnings report, beating expectations of $2.868. Following the earnings report the stock price went down -9.531%.
Which hedge fund is a major shareholder of Bio-Rad Laboratories?
Currently, no hedge funds are holding shares in BIO
---
Bio-Rad Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$374.00 (45.72% Upside)
$374.00 (45.72% Upside)
Blogger Sentiment
Bearish
BIO Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 214.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $741.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.76%
12-Months-Change
Fundamentals
Return on Equity
-24.09%
Trailing 12-Months
Asset Growth
-23.86%
Trailing 12-Months
Company Description
Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
---
BIO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a challenging landscape with significant declines in the Life Science segment and impacts from China policy changes, despite meeting some financial targets and strategic acquisitions. The overall sentiment is cautious with a focus on future improvement.Read More>---
BIO Net sales Breakdown
59.92% Clinical Diagnostics
40.06% Life Science
0.02% Other
---
BIO Stock 12 Month Forecast
Average Price Target
$374.00
▲(45.72% Upside)
Technical Analysis
Best Analysts Covering BIO
1 Year
1 Year Success Rate
6/15 ratings generated profit
1 Year Average Return
+8.35%
reiterated a buy rating 5 months ago
Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +8.35% per trade.
---